` LVTX (LAVA Therapeutics NV) vs S&P 500 Comparison - Alpha Spread

LVTX
vs
S&P 500

Over the past 12 months, LVTX has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's 7% growth.

Stocks Performance
LVTX vs S&P 500

Loading

Performance Gap
LVTX vs S&P 500

Loading
LVTX
S&P 500
Difference

Performance By Year
LVTX vs S&P 500

Loading
LVTX
S&P 500
Add Stock

Competitors Performance
LAVA Therapeutics NV vs Peers

S&P 500
LVTX
ABBV
AMGN
GILD
VRTX
Add Stock

LAVA Therapeutics NV
Glance View

Market Cap
33.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
1.96 USD
Undervaluation 34%
Intrinsic Value
Price
Back to Top